Indiana University Research & Technology Corporation
发明人:
KELLEY, Mark R.,FISHEL, Melissa L.
申请号：
EP18772627
公开号：
EP3430057A4
申请日:
2018.03.20
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
